{'52WeekChange': 0.28459716,
 'SandP52WeekChange': None,
 'address1': 'Four Tower Bridge',
 'address2': 'Suite 400 200 Barr Harbor Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 132,
 'askSize': 1000,
 'averageDailyVolume10Day': 89037,
 'averageVolume': 167865,
 'averageVolume10days': 89037,
 'beta': 1.7595,
 'beta3Year': None,
 'bid': 81.81,
 'bidSize': 800,
 'bookValue': 24.984,
 'category': None,
 'circulatingSupply': None,
 'city': 'West Conshohocken',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 108.76,
 'dayLow': 105.66,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -10.878,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1247173376,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 108.884,
 'fiftyTwoWeekHigh': 127.25,
 'fiftyTwoWeekLow': 56.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 5773898,
 'forwardEps': -12.39,
 'forwardPE': -8.657788,
 'fromCurrency': None,
 'fullTimeEmployees': 29,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.107980005,
 'heldPercentInstitutions': 0.97899,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1469404800,
 'lastSplitFactor': '1:35',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/madrigalpharma.com',
 'longBusinessSummary': 'Madrigal Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of therapeutic candidates for '
                        'the treatment of cardiovascular, metabolic, and liver '
                        "diseases. The company's lead candidate is MGL-3196, "
                        'an orally administered, small-molecule, '
                        'liver-directed, thyroid hormone receptor (THR) '
                        'Ã\x9f-selective agonist, which is in Phase II '
                        'clinical trials for the treatment of non-alcoholic '
                        'steatohepatitis and heterozygous familial '
                        'hypercholesterolemia. It is also developing MGL-3745, '
                        'a THR-Ã\x9f-selective small molecule that is in '
                        'preclinical trials. The company has research, '
                        'development, and commercialization agreement with '
                        'Hoffmann-La Roche to develop, use, sell, offer for '
                        'sale, and import various licensed products. Madrigal '
                        'Pharmaceuticals, Inc. was founded in 2011 and is '
                        'headquartered in West Conshohocken, Pennsylvania.',
 'longName': 'Madrigal Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1655090176,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_144939852',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -105003000,
 'nextFiscalYearEnd': 1640908800,
 'open': 107.58,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '484 380 9263',
 'previousClose': 108.42,
 'priceHint': 2,
 'priceToBook': 4.2935476,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 108.76,
 'regularMarketDayLow': 105.66,
 'regularMarketOpen': 107.58,
 'regularMarketPreviousClose': 108.42,
 'regularMarketPrice': 107.58,
 'regularMarketVolume': 99781,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 15429200,
 'sharesPercentSharesOut': 0.1906,
 'sharesShort': 2940250,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2857584,
 'shortName': 'Madrigal Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.3723,
 'shortRatio': 21.22,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'MDGL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -6.814,
 'twoHundredDayAverage': 92.95806,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '33c2338b-a0af-3dc0-8aac-f252490c3f9e',
 'volume': 99781,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.madrigalpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19428'}